RT Journal Article
SR Electronic
T1 Safety and Efficacy of Gemcitabine Plus Cisplatin Against Recurrent/Metastatic Nasopharyngeal Carcinoma: A Retrospective Study
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 1227
OP 1232
DO 10.21873/anticanres.16918
VO 44
IS 3
A1 KODAMA, HIROYUKI
A1 KADOWAKI, SHIGENORI
A1 NAKAZAWA, TAIKO
A1 MATSUBARA, YUKI
A1 NARITA, YUKIYA
A1 HONDA, KAZUNORI
A1 MASUISHI, TOSHIKI
A1 TANIGUCHI, HIROYA
A1 ANDO, MASASHI
A1 KOIDE, YUTARO
A1 TACHIBANA, HIROYUKI
A1 KODAIRA, TAKESHI
A1 SAWABE, MICHI
A1 TERADA, HOSHINO
A1 BEPPU, SHINTARO
A1 NISHIKAWA, DAISUKE
A1 SUZUKI, HIDENORI
A1 HANAI, NOBUHIRO
A1 MURO, KEI
YR 2024
UL http://ar.iiarjournals.org/content/44/3/1227.abstract
AB Background/Aim: Although gemcitabine plus cisplatin (GC) prolongs survival in patients with recurrent or metastatic nasopharyngeal carcinoma (R/M NPC) compared with fluorouracil plus cisplatin, no study has evaluated the efficacy and safety of GC in nonendemic regions, including Japan, yet. Therefore, we assessed the safety and efficacy of GC in Japanese patients with R/M NPC. Patients and Methods: We retrospectively reviewed patients with R/M NPC who received GC treatment at the Aichi Cancer Center Hospital from January 2017 to March 2020. The main eligibility criteria were histologically confirmed NPC, Eastern Cooperative Oncology Group performance status (ECOG PS) of 0-2, and locally recurrent disease unsuitable for local treatment or metastatic disease. The regimen was administered every 3 weeks (gemcitabine, 1,000 mg/m2 on days 1 and 8; cisplatin, 80 mg/m2 on day 1). Results: Fourteen patients (median age, 58 years) were included in the study. Two patients had an ECOG PS of 2 and 11 exhibited nonkeratinizing histology. Of the eight patients with measurable lesions, one exhibited complete response and seven exhibited partial response, with an objective response rate of 75%. Median progression-free survival and overall survival were 7.7 and 24.2 months, respectively. Common grade 3 or 4 adverse events included neutropenia (64%), thrombocytopenia (14%), and febrile neutropenia (14%). The median relative dose intensity of gemcitabine and cisplatin was 62% and 60%, respectively. No treatment-related deaths occurred. Conclusion: The GC regimen demonstrates promising activity and is tolerable in Japanese patients with R/M NPC.